THISX Fees and Costs — T. Rowe Price Health Sciences Fund, Inc., I Class
Data updated: 2026-08-27
The net expense ratio is 0.68%: a 0.63% management fee plus 0.05% other expenses. There are no sales loads or redemption fees. In fiscal 2025 the fund paid $3.8M in broker commissions, 0.0319% of average net assets, and portfolio turnover was 62%.
THISX Fees and Expenses
Annual operating expenses and sales charges of THISX. Prospectus, as of February 25, 2026.
| Annual operating expenses | |
|---|---|
| Management fee | 0.63% |
| 12b-1 fee | — |
| Other expenses | 0.05% |
| Gross expense ratio | 0.68% |
| Fee waiver | — |
| Net expense ratio | 0.68% |
| Sales charges | |
|---|---|
| Max front load | — |
| Max deferred load | — |
| Redemption fee | — |
| Expense limitation in place (N-CEN) | Yes |
| Fees waived or reduced during the year | No |
| Waived fees subject to recoupment | No |
THISX Costs Over Time
On $10,000 invested in THISX, assuming 5% a year before costs, total costs come to $448 over 5 years, cutting the return by 0.75% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Fund expenses (net expense ratio 0.68%) | $71 | $223 | $389 |
| Trading costs (broker commissions) | $3 | $10 | $18 |
| Lost growth on money paid in costs | $0 | $12 | $41 |
| Total costs | $75 | $245 | $448 |
| Value after costs | $10,425 | $11,331 | $12,315 |
| Impact on return, per year | 0.75% | 0.75% | 0.75% |
THISX Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending December 31, 2025.
- Explicit cost rate (commissions ÷ average net assets): 0.0319%
- Total broker commissions: $3.8M
- Bought from dealers (principal trades, not a cost): $285.3M
- Portfolio turnover (prospectus): 62%
- Securities lending: none during the year
THISX Agency Brokers
Commissions paid.
| Broker | Amount | Share |
|---|---|---|
| JEFFERIES LLC | $404K | 16.41% |
| RBC Capital Markets, LLC | $288K | 11.70% |
| BOFA SECURITIES, INC. | $250K | 10.17% |
| UBS AG | $243K | 9.86% |
| GOLDMAN SACHS & CO. LLC | $229K | 9.32% |
| MORGAN STANLEY & CO. LLC | $227K | 9.21% |
| J.P. MORGAN SECURITIES LLC | $218K | 8.84% |
| Citigroup Inc. | $218K | 8.84% |
| TD Securities Ltd. | $217K | 8.81% |
| LEERINK PARTNERS LLC | $168K | 6.83% |
THISX Dealer Counterparties
Securities bought directly from dealers (principal trades).
| Broker | Amount | Share |
|---|---|---|
| LEERINK PARTNERS LLC | $50.5M | 21.65% |
| JEFFERIES LLC | $39.0M | 16.73% |
| J.P. MORGAN SECURITIES LLC | $28.3M | 12.16% |
| GOLDMAN SACHS & CO. LLC | $24.6M | 10.54% |
| TD Securities Ltd. | $21.4M | 9.18% |
| MORGAN STANLEY & CO. LLC | $19.8M | 8.48% |
| Guggenheim Securities, LLC | $16.0M | 6.88% |
| BOFA SECURITIES, INC. | $15.2M | 6.53% |
| STIFEL NICOLAUS EUROPE LIMITED | $9.8M | 4.19% |
| PIPER SANDLER & CO. | $8.5M | 3.65% |
T. Rowe Price Health Sciences Fund, Inc. Share Classes
Net expense ratio and maximum front-end load of each share class, cheapest first.
| Ticker | Class | Net expense ratio | Front load |
|---|---|---|---|
| THISX | I Class | 0.68% | — |
| PRHSX | T. Rowe Price Health Sciences Fund, Inc. | 0.83% | — |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.